|
|
|
EKR Therapeutics Expands Management Team
Cedar Knolls, NJ, September 21, 2006
- EKR Therapeutics, Inc, an emerging specialty pharmaceutical
company, announces expansion of its management team with the
addition of Graham S. May as Senior Vice President and Chief Medical
Officer and Bruce Osthoff as Regional Sales Director. Dr. May joins
EKR from Esprit Pharma, and brings extensive successful global
pharmaceutical development experience while Mr. Osthoff, previously
of PDL Biopharma, brings demonstrated success in building and
managing sales teams.
“The addition of seasoned professionals like Graham and Bruce to EKR is a critical step in our company’s growth plans”, said Howard Weisman, Chairman & CEO. “We now have in place key management that will be responsible for commercializing our first product.” Richard DeSimone,
stated, “Graham comes to EKR with a strong background in all phases
of drug, medical device and biotechnology development plus
demonstrated success in leading key clinical trial programs while at
the National Institutes of Health and as former head of a global
contract research organization. Bruce’s depth in building and
managing effective sales teams will be vital to EKR as an emerging
pharmaceutical company. He brings to EKR a track record of top
performance in both hospital and private practice sales leadership
for both pharmaceutical and biotechnology companies. With their vast
industry leadership experience, Graham and Bruce will be valued
members of the EKR executive management team.” Dr. May has more
than 25 years as a pharmaceutical development physician in the drug,
medical device and biotechnology research industry in the US and
Europe. He was responsible for multiple product approvals in a wide
array of therapeutic areas. He was most recently with Esprit Pharma,
a New Jersey-based company specializing in urology and women’s
health and prior to that, with ESP Pharma, a company which focused
on the hospital acute care area. Dr. May came to the US from the UK
in 1980 as a visiting scientist at the Clinical Trials Branch of the
National Heart, Lung, and Blood Institute in Bethesda, MD. He
participated in a number of landmark cardiovascular studies. He also
held senior research positions at Hoechst-Roussel (now Sanofi-Aventis),
Pharmacia (now Pfizer), and Cytogen. He was previously a principal
with the healthcare practice of Gemini Consulting (now CapGemini), a
leading management consulting company, and President ClinTrials
Research (now Kendle), a global contract research organization,
where he oversaw US Operations. Dr. May has an undergraduate degree
from Cambridge University and is an Elected Fellow of the Faculty of
Pharmaceutical Physicians. Mr. Osthoff has over
18 years of sales experience, with a background in both
pharmaceutical and biotechnology areas, covering a wide scope of
therapeutic areas in acute and chronic care. He was most recently
Regional Sales Director with PDL Biopharma, a biotechnology company
focused on critical care in the thrombolytic and oncology segments.
Bruce also held sales management positions of increasing
responsibility with Elan Pharmaceuticals and Bristol Myers Squibb,
where he worked in both the hospital and office-based areas across a
number of therapeutic areas including neurology, cardiology and
orthopedics surgery. His consistent top performance has earned him
high recognition throughout his career, including several awards for
his effective interaction with key thought leaders in several
disease areas and innovative approaches to helping healthcare
providers become familiar with new products. Mr. Osthoff has a
Bachelor of Science in Mathematics and Statistics from the
University of Florida.
|
|
|
